> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel Backs Monovalent XBB Variant Covid Vaccine
- URL: https://www.fdaweb.com/panel-backs-monovalent-xbb-variant-covid-vaccine/
- Published: 2023-06-15T12:00:00.000Z
- Updated: 2026-09-14T18:39:29.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5154704

FDA’s Vaccines and Related Biological Products Advisory Committee 6/15 voted 21 to 0 that the Covid-19 vaccination program for the 2023-2024 season should contain a monovalent vaccine comprising the XBB-lineage variant.

Panel members essentially agreed with an FDA [briefing document](https://www.fda.gov/media/169378/download?ref=fdaweb.com) released in advance of the meeting that stated: “while vaccines based on the original virus strain can still be protective against severe disease, protection wanes with time and is reduced against subsequent waves of variant viruses. Both real-world evidence and immunogenicity data suggest that a vaccine composition that more closely matches circulating virus strains can significantly improve vaccine-induced immunogenicity and protection.”

Agency reviewers said that the current sublineages under consideration include XBB.1.5, XBB.1.16, or XBB.2.3\. The three variants have a similar spike protein, and a vaccine that targets any of the three should be effective, experts told the panel. The three vaccine makers — Pfizer-BioNTech, Moderna, and Novavax — indicated that they can produce sufficient supplies by September.